Aurora Spine has seen a rapid acceleration of sales of third-party products over the last two quarters, but those sales have cannibalized Aurora products resulting in lower margins; for context, sales of Aurora products increased less than 1% for the nine-month period ending September 30, 2019, while sales of third-party products almost doubled
For the quarter, the company saw increased sales of cervical screws, plates, and biologics offset by a decrease in cervical and lumbar cages as well as ZIP products
Exploring options including vendors allowing Aurora branding on licensed products, pricing adjustments on third-party products and acquiring FDA-cleared products to fill portfolio gaps
Expects to launch an SI joint fusion product in 1Q20 and the ZIPFlex motion-preservation implant late in 2020
ORTHOWORLD projects Aurora Spine full year 2019 revenue of $11.1 million, +27.4% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19
3Q18
$ Chg
% Chg
Spine
$2.4
$2.5
($0.1)
(5.9%)
Orthobiologics
$0.2
$0.2
$0.0
2.4%
Total
$2.5
$2.7
($0.1)
(5.4%)
9Mo 19
9Mo 18
$ Chg
% Chg
Spine
$8.0
$5.8
$2.2
38.1%
Orthobiologics
$0.5
$0.4
$0.1
33.2%
Total
$8.5
$6.2
$2.3
37.8%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Aurora Spine has seen a rapid acceleration of sales of third-party products over the last two quarters, but those sales have cannibalized Aurora products resulting in lower margins; for context, sales of Aurora products increased less than 1% for the nine-month...
Aurora Spine has seen a rapid acceleration of sales of third-party products over the last two quarters, but those sales have cannibalized Aurora products resulting in lower margins; for context, sales of Aurora products increased less than 1% for the nine-month period ending September 30, 2019, while sales of third-party products almost doubled
For the quarter, the company saw increased sales of cervical screws, plates, and biologics offset by a decrease in cervical and lumbar cages as well as ZIP products
Exploring options including vendors allowing Aurora branding on licensed products, pricing adjustments on third-party products and acquiring FDA-cleared products to fill portfolio gaps
Expects to launch an SI joint fusion product in 1Q20 and the ZIPFlex motion-preservation implant late in 2020
ORTHOWORLD projects Aurora Spine full year 2019 revenue of $11.1 million, +27.4% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19
3Q18
$ Chg
% Chg
Spine
$2.4
$2.5
($0.1)
(5.9%)
Orthobiologics
$0.2
$0.2
$0.0
2.4%
Total
$2.5
$2.7
($0.1)
(5.4%)
9Mo 19
9Mo 18
$ Chg
% Chg
Spine
$8.0
$5.8
$2.2
38.1%
Orthobiologics
$0.5
$0.4
$0.1
33.2%
Total
$8.5
$6.2
$2.3
37.8%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
